Company profile

Ticker
ABT
Exchange
Website
CEO
Robert B. Ford
Employees
Incorporated in
Location
Fiscal year end
SEC CIK
IRS number
360698440

ABT stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

29 Apr 20
2 Jul 20
31 Dec 20

News

Company financial data Financial data

Quarter (USD) Mar 20 Dec 19 Sep 19 Jun 19
Revenue 7.73B 8.31B 8.08B 7.98B
Net income 564M 1.05B 960M 1.01B
Diluted EPS 0.31 0.59 0.53 0.56
Net profit margin 7.30% 12.62% 11.89% 12.61%
Operating income 758M 1.39B 1.2B 1.21B
Net change in cash -483M -231M 954M 115M
Cash on hand 3.38B 3.86B 4.09B 3.14B
Cost of revenue 3.28B 3.43B 3.36B 3.28B
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 31.9B 30.58B 27.39B 20.85B
Net income 3.69B 2.37B 477M 1.4B
Diluted EPS 2.06 1.33 0.27 0.94
Net profit margin 11.56% 7.74% 1.74% 6.71%
Operating income 4.53B 3.65B 1.56B 3.03B
Net change in cash 16M -5.56B -9.21B 13.62B
Cash on hand 3.86B 3.84B 9.41B 18.62B
Cost of revenue 13.23B 12.71B 12.41B 9.09B

Financial data from company earnings reports

Date Owner Security Transaction Code $Price #Shares $Value #Remaining
30 Jun 20 Alpern Robert J Stock Equivalent Units Common Shares Grant Aquire A 91.43 86 7.86K 8,015
30 Jun 20 John G Stratton Stock Equivalent Units Common Shares Grant Aquire A 91.43 344 31.45K 5,434
10 Jun 20 Earnhardt Lisa D Common shares without par value Sell Dispose S 90.844 872 79.22K 72,074
10 Jun 20 Earnhardt Lisa D Common shares without par value Payment of exercise Dispose F 90.27 2,855 257.72K 72,946
4 Jun 20 Miles D White Common shares without par value Gift Dispose G 0 1,100 0 3,180,943
3 Jun 20 John F Ginascol Common shares without par value Payment of exercise Dispose F 92.62 1,768 163.75K 64,677
73.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2079 2143 -3.0%
Opened positions 107 249 -57.0%
Closed positions 171 103 +66.0%
Increased positions 829 752 +10.2%
Reduced positions 882 832 +6.0%
13F shares
Current Prev Q Change
Total value 102.71B 115.02B -10.7%
Total shares 1.3B 1.32B -1.6%
Total puts 5.48M 7.02M -21.9%
Total calls 6.7M 7.67M -12.7%
Total put/call ratio 0.8 0.9 -10.6%
Largest owners
Shares Value Change
Vanguard 155.79M $12.29B +2.6%
BLK BlackRock 128.12M $10.11B +2.7%
Capital Research Global Investors 95.87M $7.56B -15.7%
STT State Street 74.08M $5.85B +0.7%
Capital International Investors 55.78M $4.4B +17.9%
Wellington Management 43.18M $3.41B +11.9%
Massachusetts Financial Services 27.37M $2.16B -11.6%
NTRS Northern Trust 26.79M $2.11B +0.2%
BAC Bank of America 26.41M $2.08B +5.3%
MS Morgan Stanley 25.36M $2B +11.3%
Largest transactions
Shares Bought/sold Change
Capital Research Global Investors 95.87M -17.82M -15.7%
Norges Bank 0 -16.85M EXIT
FMR 15.3M -9.63M -38.6%
Capital International Investors 55.78M +8.45M +17.9%
Polen Capital Management 16.66M +7.74M +86.7%
Veritas Asset Management 5.05M +5.05M NEW
Wellington Management 43.18M +4.58M +11.9%
Vanguard 155.79M +4.01M +2.6%
FRLG Goldman Sachs 11.84M -3.89M -24.7%
Charles Schwab Investment Management 11.49M +3.7M +47.4%

Financial report summary

?
Risks
  • The manufacture of many of Abbott’s products is a highly exacting and complex process, and if Abbott or one of its suppliers encounters problems manufacturing products, Abbott’s business could suffer.
Management Discussion
  • The increase in Total Net Sales in 2019 reflects volume growth across all of Abbott’s segments.  The increase in Total Net Sales in 2018 reflects the acquisition of Alere, as well as volume growth across all of Abbott’s segments.  The price declines related to the Medical Devices segment in 2019 and 2018 primarily reflect pricing pressures on drug eluting stents (DES) as a result of market competition in the U.S. and other major markets.
  • A comparison of significant product and product group sales is as follows.  Percent changes are versus the prior year and are based on unrounded numbers.
  • n/m = percent change is not meaningful.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Bad
New words: acute, addressed, adequate, aggressive, aging, antibody, ARCHITECT, broader, broadly, CA, calculating, cardioverter, cease, CentriMag, circulatory, closed, collected, conducted, consumer, corrective, country, critical, demand, detect, detection, difficulty, disrupt, diversified, doubtful, duration, employed, EUA, Europe, exempt, experienced, facility, fighting, Ford, Funck, geographically, global, healthcare, hospital, ID, IgG, implemented, implementing, infected, interim, intraperiod, Jr, launch, launched, law, letter, level, loan, low, LVAD, meet, mobilized, multiple, nature, November, pandemic, person, political, postponed, President, progressed, promotional, proper, publicly, quarantine, RealTime, release, resynchronization, retailer, return, Robert, routine, run, safety, serology, serving, shelter, shifted, Simplifying, southeast, spread, stable, steadily, strict, subsidiary, successfully, superseded, support, Sylmar, Topic, travel, unable, volume, warning, widespread
Removed: ablation, account, achieving, Africa, agreement, Alinity, allocation, announced, apply, approval, assessing, atrial, balloon, basically, BBB, book, borrowing, Brian, capitalization, carotid, carry, catheter, classification, clinical, clinically, closure, commenced, commencement, comparison, contact, contractual, controlled, coronary, customer, decline, demonstrated, Department, designed, destination, determination, direct, discontinuation, Enabled, endovascular, entered, exercised, extend, family, fibrillation, final, Finance, force, heartbeat, hedged, immaterial, implicit, incremental, initial, invasive, irregular, largest, leaky, lease, leased, lessee, liability, maintenance, marked, marking, minimally, MitraClip, mitral, modified, MOMENTUM, obtained, office, option, organization, package, patient, Pedialyte, PediaSure, peripheral, policy, population, projected, property, pump, qualified, randomized, reagent, realizable, receiving, recognizing, recording, refinancing, regurgitation, represented, resulted, retrospective, ROU, royalty, secondary, Sensor, single, space, spending, study, supplied, survival, TactiCath, terminate, Treasury, treat, treatment, trial, vary, vessel, weighted, White, Yoor